突变型p53与其合成致死基因的研究进展

doi:10.16288/j.yczz.14-277

遗传 ›› 2015, Vol. 37 ›› Issue (4): 321-326.doi: 10.16288/j.yczz.14-277

突变型p53与其合成致死基因的研究进展

刘同阳^1,2,郭海强²,朱美妍²,黄英泽²,贾舒婷²,罗瑛²,张继虹²

1. 昆明理工大学生命科学与技术学院,昆明 650500;
2. 昆明理工大学医学院,衰老与肿瘤分子遗传学实验室,昆明 650500

收稿日期:2014-08-18 出版日期:2015-04-20 发布日期:2014-12-08
通讯作者: 张继虹,博士,教授,研究方向：分子药理学。E-mail: zhjihong2000@126.com E-mail:sunshine_tongyang@163.com
作者简介:刘同阳,硕士研究生,专业方向：肿瘤药理学。E-mail: sunshine_tongyang@163.com
基金资助:
国家自然科学基金项目(编号：81260501,U1202221)资助

Synthetic lethal genes to mutant p53

Tongyang Liu^1,2,Haiqiang Guo²,Meiyan Zhu²,Yingze Huang²,Shuting Jia²,Ying Luo²,Jihong Zhang²

1. School of Life Science and Biotechnology, Kunming University of Science and Technology, Kunming 650500, China;
2. Laboratory of Molecular Genetics of Aging and Tumor, Medical College of Kunming University of Science and Technology, Kunming 650500, China

Received:2014-08-18 Online:2015-04-20 Published:2014-12-08

摘要/Abstract

摘要： 恶性肿瘤的靶向治疗已经成为现阶段肿瘤治疗的热点。随着人们对癌基因认知的加深,借助合成致死的方法靶向治疗肿瘤已成为针对肿瘤特异性治疗的新策略。p53基因突变在肿瘤的形成和发展过程中具有重要作用。因此,了解肿瘤中与突变型p53基因有合成致死关系的靶基因的作用方式,有助于指导由突变型p53基因诱发肿瘤的个性化治疗。与突变型p53基因具有合成致死关系的靶基因可分为细胞周期调控基因和细胞非周期调控基因,文章综述了这两类靶基因与突变型p53基因如何构成合成致死作用以及此作用的现实意义。

关键词: p53, 合成致死, 合成致死的交互作用, 肿瘤

Abstract: Targeted therapy has become a powerful approach for cancer treatment. Better understanding of oncogenes as well as synthetic lethal interactions with oncogenes will lead to new strategies for tumor-specific treatment. It is well known that mutant p53 plays an important role in tumorigenesis and tumor development. Thus, understanding the synthetic lethal relationship between p53 mutations and interacting genes in tumor is critical for the personalized treatments of p53 mutant tumors. Synthetic lethal genes to mutant p53 can be divided into cell cycle regulators and non-cell cycle regulators. This paper review show these two types of target genes contribute to synthetic lethal interactions with p53 mutations and potential applications of these interactions in anticancer therapy.

Key words: p53, synthetic lethality, synthetic lethal interactions, tumor

刘同阳,郭海强,朱美妍,黄英泽,贾舒婷,罗瑛,张继虹. 突变型p53与其合成致死基因的研究进展[J]. 遗传, 2015, 37(4): 321-326.

Tongyang Liu,Haiqiang Guo,Meiyan Zhu,Yingze Huang,Shuting Jia,Ying Luo,Jihong Zhang. Synthetic lethal genes to mutant p53[J]. HEREDITAS(Beijing), 2015, 37(4): 321-326.

参考文献

[1] Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Pürfurst B, Walenta S, Mueller-Klieser W, Gräler M, Hummel M, Keller U, Buck AK, Dörken B, Willmitzer L, Reimann M, Kempa S, Lee S, Schmitt CA. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature , 2013, 501(7467): 421-425.
[2] Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov , 2011, 10(5): 351-364.
[3] Pessetto ZY, Yan Y, Bessho T, Natarajan A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat , 2012, 134(2): 511-517.
[4] Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, Van Oers J, Edelmann W, Heukamp LC, Reinhardt HC. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC . Cancer Discov , 2014, 4(5): 592-605.
[5] Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M. Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ. Apoptosis , 2012, 17(7): 691-701.
[6] Chan SL, Mok T. PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet , 2010, 376(9737): 211-213.
[7] Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA , 1989, 86(22): 8763-8767.
[8] Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. Surgeon , 2005, 3(3): 197-205.
[9] Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature , 1989, 342(6250): 705-708.
[10] Donehower LA, Harvey M, Slagle BL, Mcarthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature , 1992, 356(6366): 215-221.
[11] Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer , 2002, 2(8): 594-604.
[12] Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) , 2014, 46(3): 170-179.
[13] Kastan MB, Berkovich E. p53: a two-faced cancer gene. Nat Cell Biol , 2007, 9(5): 489-491.
[14] Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene , 1999, 18(55): 7883-7899.
[15] Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst , 1996, 88(14): 956-965.
[16] Rowley R, Hudson J, Young PG. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature , 1992, 356(6367): 353-355.
[17] Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther , 2009, 8(11): 2992-3000.
[18] Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther , 2004, 3(3): 305-313.
[19] Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. In

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

突变型p53与其合成致死基因的研究进展

Synthetic lethal genes to mutant p53

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙清玙, 周阳, 杜丽娟, 张梦珂, 王家乐, 任媛媛, 刘芳. 巨噬细胞相关基因与非小细胞肺癌预后和肿瘤微环境的分析[J]. 遗传, 2023, 45(8): 684-699.
[2]	严程浩, 白韦钰, 张智猛, 沈俊岭, 王友军, 孙建伟. STIM1在肿瘤发生及转移中的研究进展[J]. 遗传, 2023, 45(5): 395-408.
[3]	马春辉, 胡海旭, 张丽娟, 刘毅, 刘天懿. 用于循环肿瘤细胞定量分析的CK19数字PCR检测方法的建立及性能验证[J]. 遗传, 2023, 45(3): 250-260.
[4]	常栋, 刘享享, 刘睿, 孙建伟. FSCN1在乳腺癌发生发展中的作用及其调控机制[J]. 遗传, 2023, 45(2): 115-127.
[5]	郝庆刚, 孙凤桂, 严程浩, 孙建伟. MT1-MMP在肿瘤转移中的研究进展[J]. 遗传, 2022, 44(9): 745-755.
[6]	赵岩, 王晨鑫, 杨天明, 李春爽, 张丽宏, 杜冬妮, 王若曦, 王静, 魏民, 巴雪青. DNA氧化损伤8-羟鸟嘌呤与肿瘤的发生发展[J]. 遗传, 2022, 44(6): 466-477.
[7]	王翠玲, 刘信燚, 王亚会, 张争, 王治东, 周钢桥. MCM2通过抑制p53信号通路促进胆管癌细胞的增殖、迁移和侵袭[J]. 遗传, 2022, 44(3): 230-244.
[8]	寇艳妮, 岑山, 李晓宇. LINE-1在肿瘤早期诊断和治疗中的研究与应用[J]. 遗传, 2021, 43(6): 571-579.
[9]	王卓, 申笑涵, 施奇惠. 单细胞基因组测序技术新进展及其在生物医学中的应用[J]. 遗传, 2021, 43(2): 108-117.
[10]	刘倩, 李春燕. 增强子的鉴定及其在肿瘤研究中的应用[J]. 遗传, 2020, 42(9): 817-831.
[11]	赵利楠, 王娜, 杨国良, 苏现斌, 韩泽广. 基于单细胞靶向测序探究基因碱基突变的方法[J]. 遗传, 2020, 42(7): 703-712.
[12]	陈淑敏, 马铃, 岑山. Schlafen家族蛋白在肿瘤和病毒感染中的研究进展[J]. 遗传, 2020, 42(5): 444-451.
[13]	张强, 顾明亮. 单细胞测序技术及其在乳腺癌研究中的应用[J]. 遗传, 2020, 42(3): 250-268.
[14]	程香荣,胡兴琳,姜琦,黄星卫,王楠,雷蕾. 核糖体DNA转录的表观调控与肿瘤发生[J]. 遗传, 2019, 41(3): 185-192.
[15]	李鑫,李梦玮,张依楠,徐寒梅. 常用肿瘤基因分析方法及基于TCGA数据库的分析应用[J]. 遗传, 2019, 41(3): 234-242.